Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced the approval of Levamlodipine Besilate Tablets by the National Medical Products Administration of China. This development signifies a strategic advancement in their product offerings, potentially enhancing their market position in the pharmaceutical industry by addressing key health conditions like hypertension and angina.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company primarily offers products for the treatment of conditions such as hypertension and angina, with a market focus on drug consistency and quality evaluation.
Average Trading Volume: 14,563,947
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.5B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.